Time to focus on outcome assessment tools for childhood vasculitis by Demirkaya, Erkan et al.
REVIEW Open Access
Time to focus on outcome assessment tools for
childhood vasculitis
Erkan Demirkaya
1*, Raashid Luqmani
2, Nuray Aktay Ayaz
3, Abdulbaki Karaoglu
4 and Seza Ozen
5, for
the FMF Arthritis Vasculitis and Orphan Disease Research in Paediatric Rheumatology (FAVOR)
Abstract
Childhood systemic vasculitides are a group of rare diseases with multi-organ involvement and potentially
devastating consequences. After establishment of new classification criteria (Ankara consensus conference in 2008),
it is now time to establish measures for proper definition of activity and damage in childhood primary vasculitis. By
comparison to adult vasculitis, there is no consensus for indices of activity and damage assessment in childhood
vasculitis. Assessment of disease activity is likely to become a major area of interest in pediatric rheumatology in
the near future. After defining the classification criteria for primary systemic childhood vasculitis, the next step was
to perform a validation study using the original Birmingham vasculitis activity score as well as the disease extent
index to measure disease activity in childhood vasculitis. Presently, there are efforts in place to develop a pediatric
vasculitis activity score. This paper reviews the current understanding about the assessment tools (i.e., clinical
features, laboratory tests, radiologic assessments, etc.) widely used for evaluation of the disease activity and
damage status of the children with vasculitis.
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Background
The primary systemic vasculitides (PSV) in children
encompass a group of rare diseases that are characterized
by the inflammation of blood vessels [1]. Although
Henoch-Schonlein purpura (HSP) and Kawasaki disease
(KD) are quite common forms of vasculitis, polyarteritis
nodosa (PAN), Wegener’s granulomatosis (WG) and
Takayasu arteritis (TA) are diagnosed less commonly in
children. Because PAN, WG, and TA affect many body
systems, they have a wide range of clinical presentation
and, if left untreated, follow a chronic relapsing course
with high mortality and morbidity. With the wider use of
immunosuppressive agents, both mortality and morbidity
rates have been declining in childhood vasculitides [2].
The majority of children with HSP experience a full
and uneventful recovery. Primary outcome measures for
H S Pa r er e n a ls u r v i v a la n dp r e s e n c eo fu r i n a r y
abnormalities or hypertension. For unselected patients
with HSP, the risk of end stage renal disease (ESRD) is
reportedly very low, between 1.5% and 3% [3]. Recently
B u t a n ie ta l .d e m o n s t r a t e dt h a te v e ni na nu n s e l e c t e d
population of patients who had HSP glomerulonephritis
in childhood (n = 65), a significant proportion [n = 12
(23%)] progress to ESRD on long-term follow-up (20
years). They reported that the only factor associated
with development of ESRD was the use of cytotoxic
agents [4].
Prognosis for individuals with PAN varies with a better
outcome in children compared to adult onset disease
where the mortality rate can be as high as 20-30% despite
aggressive therapy [5]. Brogan et al. reported the mortal-
ity rate for PAN in children as approximately 10% [6].
Despite the new immunosuppressive and immunomo-
dulatory therapies, WG, microscopic polyangiitis (MPA)
and Churg-Strauss syndrome (CSS) still carry consider-
able morbidity and mortality mainly due to progressive
renal failure or aggressive respiratory involvement. In a
recent report by Cabral et al., significant renal involve-
ment was found in 27 out of reported 117 children with
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involvement requiring continuous oxygen therapy or
mechanical ventilation was observed in 19% and 11%,
respectively [7]. Akikusa et al. reported that significant
long-term renal impairment still occurs in 17-40% of
children with WG [8]. The mortality rate for pediatric
WG was 12% in another pediatric series [9]. The prog-
n o s i sf o rM P Ai ss i m i l a rt ot h a to fP A Ni nt e r m so f
mortality, and 18% for CSS in children according to the
most recent series [10,11].
As a result of increased survival and well being in
these patients, disease classification and assessment have
emerged as important considerations. Established classi-
fication criteria are necessary in order to proceed with
the development of future epidemiological studies and
clinical trials in PSV.
In 1990, the American College of Rheumatology
(ACR) grouped systemic vasculitides and proposed clas-
sification criteria for adult patients [12-15]. However,
this system overlooked the presence of the antineutro-
phil cytoplasmic antibody (ANCA) in some forms of
vasculitis, and completely overlooked microscopic poly-
angiitis (MPA). At the 1994 Chapel Hill Consensus
Conference, vasculitis definitions were published, but
these definitions were not designed to classify the vascu-
litides [16]. Currently, a working group supported by
the European League Against Rheumatism (EULAR)
and the ACR is revising the definitions and classification
criteria for adult vasculitis (http://www.clinicaltrials.gov,
NCT01066208). Though children and adults share many
features of these rare disorders, ACR classification cri-
teria developed for adults were not appropriate for use
in children. The patient groups upon which the ACR
had based the vasculitis classification criteria did not
include children [17]. In 2005, the European League
Against Rheumatism/Pediatric Rheumatology European
Society (EULAR/PReS) vasculitis working group pro-
posed new classification criteria for children with
vasculitis predominantly according to vessel size, as fol-
lows: small [HSP, childhood Wegener’s granulomatosis
(c-WG)], medium [KD and childhood polyarteritis
nodosa (c-PAN)], and large [childhood Takayasu arteri-
tis, (c-TA)] [18]. The criteria were validated for use by
EULAR, PReS and Paediatric Rheumatology Interna-
tional Trials Organisation (PRINTO). At the 2008
Ankara Consensus Conference, the final consensus was
reached and the reports were published in 2010 for clas-
sification of childhood vasculitis (Table 1) [18-20].
Highly sensitive and specific validated definitions for
HSP, c-PAN, c-WG and c-TA were established. It was
clear that with the aid of this classification scheme, it
would become easier to group patients, to conduct mul-
ticenter collaborative clinical trials and studies, and to
manage individual patients.
The site of involvement, the size of the affected vessel,
and the extent of involvement defne the clinical features
of vasculitis in children. Unlike the situation in adult
vasculitis, HSP and KD are the most frequently encoun-
tered vasculitis sub-groups in children [21,22]. They
both usually have an acute onset and a self-limiting
course. But similar to adults, although very rare, c-PAN,
c-WG and c-TA have an insidious course in children.
Histopathological evaluation or imaging techniques such
as angiography are gold standards for their diagnoses as
in adults.
If left untreated, the PSV have a higher rate of mor-
bidity and mortality. Although new treatment regimens
have reduced these rates, complications due to multi-
organ involvement of the vasculitis or the medications
used are still an important problem.
Since new classification tools are now available to
pediatricians as outlined above, it is time to consider the
development of outcome assessment tools for childhood
vasculitides. Assessment of disease activity is likely to
become a new and crucial focus of research in pediatric
rheumatology. In the last decade, disease activity indices
Table 1 Classification of Childhood Vasculitis by Özen et al.
Predominantly
large-vessel
vasculitis
Predominantly
medium-sized vessel
vasculitis
Predominantly small-vessel vasculitis Other vasculitides
Takayasu arteritis Childhood polyarteritis
nodosa (c-PAN)
Granulomatous:
Wegener granulomatosis, Churg-Strauss
syndrome
Behçet Disease
Cutaneous polyarteritis Non-granulomatous:
Henoch-Scönlein purpura, Microspcopic
polyangiitis, Hypocomplementemic
urticarial vasculitis
Vasculitis secondary to infection (including Hep B
associated PAN), malignancies and drugs, including
hypersensitivity vasculitis
Kawasaki Disease Vasculitis associated with connective tissue diseases
Isolated vasculitis of the central nervous system
Cogan syndrome
Unclassified
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(JIA), juvenile dermatomyositis, systemic lupus erythe-
matosus (SLE); however, there have been no disease
assessment tools defined and validated yet specifically
for PSV [23-27].
General Approach to Outcome in Pediatric
Systemic Vasculitis
Physical examination, laboratory assessment, histopatho-
logical evaluations and radiological investigations are
important tools both in the diagnosis and assessment of
disease activity in PSV [28,29].
Physical examination
Children usually have fever, malaise, weight loss, myal-
gias and rashes, but these symptoms are non-specific for
vasculitis. It is clear that while thorough history-taking
and a careful physical examination are crucial for the
correct diagnosis, the subsequent assessments over time
of disease activity, disease progression, and need for
effective treatment protocols have a similar important
role in the child’s outcome. Although remission is
usually achieved, acute exacerbations and chronic devas-
tating complications are still encountered. There are
several clinical and/or laboratory indicators alerting the
physician to the possibility of a disease flare, the most
important of which is the clinical evaluation of the
patient.
Laboratory tools
C-reactive protein (CRP), erythrocyte sedimentation rate
(ESR) and leukocyte counts are usually elevated during
active disease, but these tests are not specific because
they are frequently elevated during infections as well
[5,8,9]. In addition, normal levels do not always exclude
the presence of active disease. The relation between dis-
ease activity and acute phase reactants such as ESR,
CRP levels have been studied in adults. However it has
been reported in only one pediatric study which showed
a poor correlation between scoring indices (BVAS and
PGA) and acute phase reactants (ESR and CRP) [28,29].
A urinalysis as well as liver and kidney function tests
may indicate involvement of organ systems but they are
likewise non-specific for active disease. They may be
abnormal due to infection, co-morbidity, organ damage
or drug toxicity.
ANCA- associated vasculitides (WG, MPA, CSS) are
seen less commonly in children but they may result in
significant renal or respiratory system damage. The
introduction of widespread ANCA testing has assisted
in the differential diagnosis of adult vasculitis. The accu-
racy of ANCA in determining the disease activity and
distinguishing relapse is controversial [30]. In the adult
literature, there is no consensus about the value of c-
ANCA titers to assess/predict disease activity or pro-
gression [31-33]. In one study, only 24% of the patients
had an increased level of c-ANCA before occurrence of
a relapse [34]. In contrast, lower rates of c-ANCA posi-
tivity was reported in childhoodWG which is usually
more localized in children. In the absence of clinical evi-
dence of disease activity, the presence of the c-AnCA
positivity is not sufficient unto itself to justify aggressive
immunosuppressive therapy in children who may be
adversely affected by the burden of these medications.
Anti-endothelial antibodies, von Willebrand factor and
adhesion molecules are also studied in adults as markers
of disease activity; however, they are nonspecific for dis-
ease activity as they reflect the endothelial impact of
vasculitis [35-37]. These markers may be used more spe-
cifically with clinical assessment tools.
Although histopathological evaluation is the gold stan-
dard in making the diagnosis of vasculitis, its sensitivity
and specificity differs between vasculitis subgroups.
Furthermore, even in active renal disease, in which his-
topathological findings are almost always positive, it is
impractical to re-biopsy patients for assessing disease
activity.
Radiologic evaluation
X-rays, ultrasonography, computerized tomography
(CT), magnetic resonance imaging (MRI), positron emis-
sion tomography (PET) and conventional angiography
are the main imaging techniques used in diagnosis of
vasculitis and determination of organ damage [38-42].
MRI is a good non-invasive diagnostic and follow-up
technique for TA [38]. In adults, CT is helpful for diag-
nosing ANCA-associated vasculitis, especially if there is
upper or lower airway involvement; in children, it is
very useful for detection of coronary aneurysms and ste-
nosis in KD [41]. Ultrasound is an operator- dependent
technique. Although CT and radiograph imaging are
important, they have limitations due to contrast material
and radiation exposure in children. MRI and ultrasound
techniques may be of more practical use.
Lessons From Adult Experience
Multicenter trials in adult rheumatology have provided
evidence-based data for the treatment and management
of adult vasculitides, under the structure of European
Vaculitis Study Group (EUVAS) and other organizations
such as the International Network for the Study of Sys-
temic Vasculitis, the French Vasculitis Study Group and
the Vasculitis Clinical Research Consortium (VCRC)
[43-45]. These groups have independently conducted
randomized controlled clinical trials (RCTs) using stan-
dardized clinical measurement scores. The results of
these trials have had a significant impact on patient care
in clinical practice [46-48].
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Standing Committee for International clinical studies
including therapeutics, a group of experts was formed
including members of EUVAS and VCRC. The organiza-
tional progress of vasculitis investigators worldwide
require parallel improvements in the ability to measure
and record vasculitis activity in a uniform manner. The
tools for the disease assessment and outcome measures
were recommended and recently published by EULAR
for conducting clinical studies and/or clinical trials in
systemic vasculitis for adults (Table 2) [49].
Birmingham Vasculitis Activity Score (BVAS)
In 1994, the original version of BVAS was developed by
a group of physicians dealing with vasculitis and vali-
dated by the same study. Later on, it was refined as
BVAS v2 in 1997 [50,51]. The most recent version of
BVAS (v3.0) has been refined from previous versions,
based on extensive use in clinical trials and validated in
a range of over 300 adults with vasculitis. The number
o fi t e m sw a sr e d u c e dt o5 6f r o m6 6i nB V A S( v . 3 )[ 2 9 ] .
BVAS aims to define the active disease requiring treat-
ment. It assesses 9 organ systems (systemic, cutaneous,
mucous membranes/eyes, ear/nose/throat, chest, cardio-
vascular, abdominal, renal and nervous system). Each
individual item is recorded as being newly present or
worsening within the last 4 weeks. The presence or
absence of each item is recorded and each item has a
weighted score. The total score of items give an objec-
tive measure for disease activity; the higher the score,
the more active the vasculitis.
Disease Extent Index
This instrument has been developed as a complemen-
tary measure to disease activity as measured by the
BVAS. It has been validated for use in patients with
Wegener’s granulomatosis and partially validated in
patients with hepatitis C virus-associated cryoglobuline-
mic vasculitis [52,53]. DEI was used in three RCTs and
several open-label studies [53-56]. The DEI can be
applied to patients with active disease as well as patients
with partial or complete remission. The score sheet
assesses 11 organ systems. Each system, excluding con-
stitutional symptoms (score = 1), is weighted as 2 points
if active vasculitis is present at the time of assessment.
Each body system is scored only once, irrespective of
the number of affected organ within the organ system
or the severity of the respective manifestation. The final
score for DEI may reach a maximum of 21. There is no
distinction between new, worse or persistent disease.
However, previous activity or damage is not counted.
The DEI can complement the BVAS by showing
whether a high BVAS score is due to multiorgan invol-
vement or severe involvement of 1 organ.
New insights in pediatric vasculitis
Pediatric rheumatologists have recently focused on
developing outcome instruments in childhood vasculitis.
Although BVAS has been validated in a large number of
adult patients and accepted as the gold standard for
assessment of disease activity, it may not be suitable for
use in children with vasculitis, partly because some
items are specific to adults. The items of BVAS could
be re-evaluated according to the presence and frequency
of clinical features of pediatric vasculitides, with some
modification of items, deletion of some items and addi-
tion of new pediatric vasculitis specific items, as well as
a change to the weighted scores. First and foremost is
that the normal reference ranges in children are differ-
ent from adults such as blood pressure, serum creati-
nine, amount of proteinuria, glomerular filtration rate or
cut-off for significant weight loss. In addition, disease
presentations as well as some clinical features and out-
come are different in children compared to adults.
Arthritis is more common in children with HSP and
renal involvement usually increases with age [57]. WG
is less frequent in children but subglottic stenosis is
seen more commonly than in adults [9]. The other most
apparent differences between adult and pediatric
patients with vasculitis are developmental and growth
issues, differences in functional, educational and social
impact of longstanding disease and absence of adult co-
morbidities. There are also distinctive drug pharmacoki-
netics and toxicity profiles in children.
Table 2 EULAR recommendations for disease assessment and outcome measures in systemic vasculitis for adults
Disease activity Disease extent Physician global
assessment
Damage Quality of life and generic
health status measures
Birmingham Vasculitis Activity Score (BVAS
Version 1)
The Disease Extent
Index (DEI)
The Vasculitis
Damage Index (VDI)
Short form-36 (SF-36)
Birmingham Vasculitis Activity Score (BVAS
Version 2)
Birmingham Vasculitis Activity Score (BVAS
Version 3)
Birmingham Vasculitis Activity Score for
Wegener’s granulomatosis (BVAS/WG).
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ate active disease from damage or treatment complica-
tions and predict the functional outcome. Presently,
there are efforts in place to develop a pediatric version
of BVAS that is called pediatric vasculitis activity score
(PVAS). The PVAS project, a newly developed tool for
the evaluation of systemic vasculitis in children, was
built on previous successful international collaboration
of the PReS Vasculitis Working Party for childhood sys-
temic vasculitis, in cooperation with members of Child-
hood Arthritis and Rheumatology Research Alliance
(CARRA) from North America. Preliminary work from
these investigators has derived a version of PVAS which
has been validated in paper cases. Currently, PVAS is in
a validation process on real pediatric vasculitis cases
that will determine feasibility, reliability, internal consis-
tency and tool responsiveness to change. The PVAS
score will be correlated with routine clinical laboratory
values such as ESR, CRP and, physician’s global assess-
ment of disease activity. The PVAS is meant to help
physicians assess an individual patient’sr e s p o n s et o
therapy and also serve as an outcome measures in clini-
cal trials. Thus it might have a positive impact on the
ability to research new therapies.
PVAS is designed to record new or worsening clinical
features of active vasculitis that is attributable to the
current state of the disease, after excluding other causes
such as infection, hypertension, etc. PVAS includes a set
of items that involves nine organ based systems similar
to BVAS. The presence or absence of each weighted
item gives a maximum score for each organ system. The
sum of all nine organ systems determines the total score
that shows the disease activity of each patient at the
time of evaluation. If the patient is evaluated for the
first time by the physician, all features of the disease are
considered active/new irrespective of the time period.
On subsequent evaluations, time has a more important
role in formal distinguishing “new” active disease pre-
sentation from “persistent”, low-grade or festering dis-
ease. Disease presentation is considered “active” if it has
been newly present over the 4 weeks prior to the time
of evaluation or whether it has worsened since the last
evaluation and has been lasting for up to 3 months in
total. The paper sheet includes the tick box: “No new/
worse disease” and should be marked if there is no new/
worse abnormality present in any of the systems. On
this basis, the calculated score for PVAS will contain
only values representing persistent disease. In other
words, it represents no new disease and means all of the
active features are persistent. If one item among the
item list represents either new or worse disease, then
the “No new/worse disease” box should not be checked.
After the PRINTO and PReS defined the classification
criteria for primary systemic childhood vasculitis, they
performed the first validation study in this field to use
the original BVAS (v.3) and disease extent index (DEI)
for the measurement of disease activity in childhood
vasculitis [28]. In this study, the analysis data set
included 796 patients with primary systemic vasculitides.
There were 669 HSP, 80 c-PAN, 25 c-WG and 22 TA
patients. The authors found a strong correlation
between the BVAS v.3 and DEI (rs = 0.80) while correla-
tion with PGA were moderate (rs =0 . 4 9 )a n dp o o rw i t h
CRP and ESR (rs = 0.34, rs = 0.31). Responsiveness was
good for BVAS (SRM = 1.38) and DEI (SRM = 1.9).
BVAS and DEI also seem sufficiently sensitive to detect
the change in disease status over time. These two tools
have been able to differentiate different vasculitis groups
according to their results among childhood vasculitis.
The correlation with the physician global assessment of
disease activity was moderate in our series, similar to
the data reported in the original BVAS paper by Luq-
mani et al. where the correlation was poor [50]. With
this study, the authors demonstrated that the BVAS and
DEI correlated poorly with ESR and CRP and the corre-
lation did not improve when the analysis was repeated
without the HSP patients that are known to have nor-
mal or low level of inflammation. On the other hand,
there was a good correlation among these two instru-
ments suggesting that the simplest DEI might be inter-
changeably used as an alternative measure to assess the
disease activity in vasculitis, at least in children. The use
of BVAS in children is hampered by the differences in
both the spectrum of active disease manifestations as
well as by some of the item definitions; this problem
was overcome by the modification of the BVAS glossary
to take into account pediatric specificities. Therefore the
validation of the BVAS and DEI has to be considered
the first step for the proper evaluation of disease
activity.
Patient-reported outcome measurements (PROMs)
The inclusion of PROMs is another standard research
practice for rheumatic diseases in adults and children
and provides a report of the status of a patient’sh e a l t h
condition that comes directly from the patient. There
are several examples of disease specific well-defined and
reliable instruments in children with JIA such as health-
related quality of life (HRQOL), the juvenile arthritis
multi-dimensional assessment report (JAMAR), ques-
tionnaires for the evaluation of functional ability, and
visual analog scales (VAS) for rating of child’so v e r a l l
well-being and intensity of pain. Recently a new tool
named simple measure of the impact of lupus erythema-
tosus in youngsters (SMILEY) has been developed for
systemic lupus erythematosus (SLE) [58-61].
These instruments can be completed by the patients
or parents on their behalf. Despite the development of
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damage, there are no vasculitis-specific instruments
measuring patient-estimated burdens of disease. Herlyn
et al. recently published a study of PROMs among
patients with vasculitis indicating that there were many
manifestations of disease (fatigue, reduced energy level)
that were quite important to patients but not measured
with the outcome instruments currently included in
clinical trials of vasculitis [62].
Patients’ subjective experience should be a part of the
outcome measurement process since they are the true
experts about their disease. Therefore, the importance
of the use of PROMs in medical outcome assessment
(the OMERACT initiative) is also emphasized by the
vasculitis clinical research community. Introduction of
patient-based outcome assessments to childhood vascu-
litis will be one of the future directions.
Damage
While dealing with disease activity, it is also important
not to forget to define the amount of damage present in
the patient. In 1997 the Vasculitis Damage Index (VDI)
was defined for measuring the amount of damage [63]. It
predicts the damage in 11 organ systems with irreversible
pathology lasting for more than 3 months. Damage may
be due to the disease or to the therapy. VDI has a role in
predicting the outcome of the disease and probable mor-
tality. A childhood version of the damage index is
needed, because many items used in the adult version are
not applicable to children such as the cut-off level to
define hypertension. In addition, some aspects of damage
are unique to children such as growth and development.
A pediatric version of the VDI (PVDI) is being developed,
as has previously been done with PVAS.
Conclusion
While adult experience provides the backbone of most
of the current practice in childhood vasculitis, there are
some challenges in treatments and outcome measure-
ment tools. The PReS has established a vasculitis study
working group with international collaboration to cope
with this problem. On behalf of the PReS and EULAR,
PRINTO undertook a multinational, multicenter colla-
boration to validate BVAS and DEI as the activity mea-
sures. Because some of the items in BVAS were not
considered appropriate for the pediatric population, the
PReS Vasculitis Working Party developed the Pediatric
Vasculitis Activity Score “PVAS” as a tool to assess dis-
ease activity in clinical trials based on the concept of the
adult BVAS scoring system. After defining the outcome
measures, defining the damage will be an absolute
necessity in pediatric rheumatology. Therefore, the
PVDI should be developed soon and be an important
component of outcome measures to be used in clinical
trials of vasculitis treatment in children. Lastly, it is
clear that both patient-based outcome assessments and
evaluation of the response to treatment during followup
are very important as well and better tools for assess-
ment of these parameters need to be developed soon.
After the PVAS and PVDI are validated, these tools will
be next on the agenda in pediatric rheumatology.
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